Literature DB >> 17303583

Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities.

Roberto Gnavi1, Alessandro Migliardi, Moreno Demaria, Alessio Petrelli, Adele Caprioglio, Giuseppe Costa.   

Abstract

BACKGROUND: Socio-demographic and clinical characteristics can influence statins prescribing for the secondary prevention of ischaemic heart disease (IHD). We studied the determinants of the prescription of statins in people with IHD in a population in Italy, the country with the lowest prescribing rate in Europe.
METHODS: All 2001/2002 residents in Torino, aged 30-85 years, with a hospital discharge diagnosis of IHD were linked to the regional Database of Drug Prescriptions to identify those persons who, within 3 months after discharge, had been prescribed statins. Log-binomial models were used to test statins prescription associations with clinical and socio-demographic characteristics.
RESULTS: Statins were prescribed to 31.0% of 7446 patients. Among persons >74 years of age, the prescription rate was 40% lower than that found for younger persons. A positive association was also found for: female gender, being married, a main discharge diagnosis of acute myocardial infarction, revascularization, diabetes and discharge from a cardiology ward. Age was an important effect modifier of the relationship between the prescribing rate and social, but not clinical, determinants.
CONCLUSIONS: The prevention of IHD with statins is influenced by age, clinical and social factors. The prescribing rate is higher among population groups for whom statins are of proven efficacy. Among patients for whom the efficacy is uncertain, the decision to prescribe is influenced by non-clinical factors, suggesting that there exist both age-based and social-based mechanisms of rationing. Age and social determinants act in concert to further reduce the propensity of physicians to prescribe statins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303583     DOI: 10.1093/eurpub/ckm005

Source DB:  PubMed          Journal:  Eur J Public Health        ISSN: 1101-1262            Impact factor:   3.367


  16 in total

Review 1.  Statins in the primary prevention of cardiovascular disease.

Authors:  Željko Reiner
Journal:  Nat Rev Cardiol       Date:  2013-06-04       Impact factor: 32.419

2.  Age- and gender-related differences in drug utilisation and adverse drug reaction patterns among patients in a coronary care unit.

Authors:  Nitin Subhashchandra Kunnoor; Padmini Devi; Deepak Yogesh Kamath; Naveen Anthony; Jesso George
Journal:  Singapore Med J       Date:  2014-04       Impact factor: 1.858

3.  Statin-prescribing trends for primary and secondary prevention of cardiovascular disease.

Authors:  Felicity Brown; Alexander Singer; Alan Katz; Gerald Konrad
Journal:  Can Fam Physician       Date:  2017-11-14       Impact factor: 3.275

Review 4.  Primary prevention of cardiovascular disease with statins in the elderly.

Authors:  Zeljko Reiner
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

5.  Age equity in different models of primary care practice in Ontario.

Authors:  Simone Dahrouge; William Hogg; Meltem Tuna; Grant Russell; Rose Ann Devlin; Peter Tugwell; Elizabeth Kristjansson
Journal:  Can Fam Physician       Date:  2011-11       Impact factor: 3.275

6.  Variation in initiating secondary prevention after myocardial infarction by hospitals and physicians, 1997 through 2004.

Authors:  Andrea V Margulis; Niteesh K Choudhry; Colin R Dormuth; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-04-28       Impact factor: 2.890

7.  Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study.

Authors:  James P Sheppard; Kate Fletcher; Richard J McManus; Jonathan Mant
Journal:  Br J Gen Pract       Date:  2014-01       Impact factor: 5.386

8.  Social stratification in the dissemination of statins after stroke in Sweden.

Authors:  Maria Sjölander; Marie Eriksson; Eva-Lotta Glader
Journal:  Eur J Clin Pharmacol       Date:  2012-11-28       Impact factor: 2.953

Review 9.  Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.

Authors:  Sydney B Long; Michael J Blaha; Roger S Blumenthal; Erin D Michos
Journal:  Clin Interv Aging       Date:  2010-12-22       Impact factor: 4.458

10.  Income-related inequity in initiation of evidence-based therapies among patients with acute myocardial infarction.

Authors:  Gillian E Hanley; Steve Morgan; Robert J Reid
Journal:  J Gen Intern Med       Date:  2011-07-13       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.